Protocol Ledger

NCT03566238 · Phase III · COMPLETED

This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2

Interventional Phase III clinical trial protocol NCT03566238 sponsored by Albireo in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-05-16 Enrollment: 62 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03566238
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)62 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03566238
Protocol FieldVerified Registry Value
NCT IdentifierNCT03566238
Consolidated Lead SponsorAlbireo
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment62 participants (ACTUAL)
Registered Start Date2018-05-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI